High-throughput discovery platform for modulators of cardiac muscle proteins to treat heart failure

用于治疗心力衰竭的心肌蛋白调节剂的高通量发现平台

• 批准号: 10483462
• 负责人: Brett A Colson
• 金额: $ 30.65万
• 依托单位: PHOTONIC PHARMA, LLC
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-04-15 至 2024-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10483462
• 关键词: Actins; Address; Adult; Affect; Affinity; Animal Model; Anisotropy; Arizona; Binding; Binding Proteins; Biochemical; Biochemistry; Biological Assay; Biophysics; Biosensor; Biotechnology; Calorimetry; Cardiac; Cardiac Myocytes; Cardiac Myosins; Cell model; Cells; Collaborations; Cyclic AMP-Dependent Protein Kinases; Detection; Development; Doctor of Philosophy; Drug Screening; Drug Targeting; Engineering; Fluorescence; Fluorescence Resonance Energy Transfer; Fluorescent Probes; Functional disorder; Goals; Health; Heart; Heart failure; Hypertrophic Cardiomyopathy; In Vitro; Leadership; Legal patent; Letters; Libraries; Marketing; Measurement; Methods; Molecular Medicine; Muscle Proteins; Myocardium; Myosin ATPase; N-terminal; Pathologic; Patient-Focused Outcomes; Patients; Pharmaceutical Chemistry; Pharmaceutical Preparations; Pharmacologic Substance; Phase; Phosphorylation; Physiological; Physiology; Problem Solving; Protein Conformation; Proteins; Publications; Quality of life; Relaxation; Research; Series; Site; Small Business Innovation Research Grant; Specificity; Speed; Structure; Survival Rate; Technology; Testing; Therapeutic; Time; Tissues; Titrations; Treatment Failure; Universities; Validation; Work; base; blood pump; cardiac tissue engineering; clinically relevant; drug candidate; drug discovery; efficacy evaluation; experience; heart function; high throughput screening; improved; in vivo; induced pluripotent stem cell; innovation; instrumentation; interest; myosin-binding protein C; novel; novel therapeutics; personalized medicine; phosphorescence; photonics; product development; protein complex; protein function; screening; small molecule; small molecule libraries; symptomatic improvement; technology development; therapeutic development; therapeutic target

Project Summary This Phase I SBIR collaboration between Photonic Pharma LLC (PP) and the University of Arizona (UA) will establish proof-of-concept for an innovative drug-discovery campaign for treatment of heart failure (HF), targeting cardiac myosin-binding protein C (MyBP-C). There is an urgent need for novel therapies for HF, a major health problem affecting 1 in 30 adults in the US. MyBP-C has been identified as a therapeutic target for correcting HF. Phosphorylation affects N-terminal MyBP-C structure, affecting its binding to actin and myosin, modulating contraction and relaxation. Therefore, targeting MyBP-C with drugs that mimic phosphorylation and/or modulate its binding to actin or myosin is a promising approach to treatment of heart failure. PP has developed patented technology for fluorescent protein biosensors and high-throughput screening (HTS) based on time-resolved fluorescence lifetime (FLT) detection, seeking breakthroughs in the early phase of drug discovery with unprecedented quality, speed, and precision. UA brings expertise in MyBP-C and cardiac muscle biophysics, biochemistry, and physiology. In a new publication, this collaborative team has identified the first compounds that bind to MyBP-C and modulate its interaction with actin. The goal of this project is to demonstrate proof-of-concept that drug targeting of MyBP-C is a powerful platform for discovery of novel therapies to affect cardiac muscle protein function and ultimately patient outcomes in heart failure. Aim 1 studies will use a primary HTS assay of a 50,000-compound library of diverse and drug-like small molecules (now justified by recently completed screens on a small validation library), using a novel FRET assay, to find compounds that affect the interaction of MyBP-C-with actin. The fluorescence lifetime FRET (FLT-FRET) assay uses site-specific fluorescent probes attached to actin and MyBP-C domains C0-C2. FLT measurements provide a precise readout of protein binding and conformation. Small-molecule Hits will be evaluated to select compounds with highest affinity interactions and/or sensitivity to phosphorylation. Aim 2 studies will use secondary assays (lower throughput) to determine efficacy of Hit compounds on function. Selected compounds will be evaluated by biochemical, biophysical, and physiological assays for effects on MyBP-C function, actin binding, and contractility in cardiac cells. These novel screening strategies address the key missing aspect, early-phase structure-based drug discovery, to enable MyBP-C therapeutic development, as needed to fine- tune contractility and improve patient quality of life and survival. In Phase I we will validate the HTS assay for application to commercial-scale drug screening. In Phase II we will enhance potency and specificity with medicinal chemistry, evaluating the most promising compounds in increasingly physiological/pathological conditions for the heart failure indication. Letters from major pharmaceutical companies indicate great commercial potential for this technology, applied to this specific target and others. Our long-term goal: address the unmet need for novel heart failure therapies that are commercially validated.

项目摘要 Photonic Pharma LLC（PP）与亚利桑那大学（UA）之间的I阶段IS合作 将建立概念概念，以进行创新的药物解决心脏衰竭运动（HF）， 靶向心脏肌球蛋白结合蛋白C（MYBP-C）。迫切需要HF的新型疗法 影响美国30名成年人中有1个的主要健康问题。 MYBP-C已被确定为 纠正HF。磷酸化会影响N末端MYBP-C结构，影响其与肌动蛋白和肌球蛋白的结合， 调节收缩和放松。因此，用模仿磷酸化的药物靶向MYBP-C 和/或调节其与肌动蛋白或肌球蛋白的结合是治疗心力衰竭的有前途的方法。 PP有 开发了用于荧光蛋白生物传感器和高通量筛选（HTS）的专利技术 在时间分辨的荧光寿命（FLT）检测上，在药物的早期寻求突破 以前所未有的质量，速度和精度发现。 UA具有MYBP-C和心脏的专业知识 肌肉生物物理学，生物化学和生理学。在新的出版物中，这个合作团队已经确定 与MyBP-C结合并调节其与肌动蛋白的相互作用的第一批化合物。这个项目的目标是 证明概念证明MYBP-C的药物靶向是发现新颖的平台 影响心脏肌肉蛋白功能并最终在心力衰竭中患者结局的疗法。目标1 研究将使用50,000个不同分子和类似药物的小分子的原始HTS测定法 （现在由小型验证库上最近完成的屏幕辩护），使用新颖的FRET分析来查找 影响mybp-c与肌动蛋白相互作用的化合物。荧光寿命品格（flt-fret） 测定使用附着在肌动蛋白和MYBP-C结构域C0-C2上的特定位点荧光探针。 FLT测量 提供蛋白质结合和构象的精确读数。将评估小分子命中以选择 具有最高亲和力相互作用的化合物和/或对磷酸化的敏感性。 AIM 2研究将使用 次级测定（较低的吞吐量）以确定命中化合物对功能的功效。选定的化合物 将通过生化，生物物理和生理测定法对MYBP-C功能，肌动蛋白的影响进行评估 结合和心脏细胞的收缩力。这些新颖的筛选策略涉及关键缺失方面， 基于早期结构的早期结构的药物发现，以促进MYBP-C治疗性发育 调整收缩力并提高患者的生活质量和生存。在第一阶段，我们将验证HTS测定法 适用于商业规模的药物筛查。在第二阶段，我们将通过 药物化学，评估越来越多的生理/病理学中最有希望的化合物 心力衰竭指示的条件。主要制药公司的来信表明很棒 该技术的商业潜力应用于该特定目标和其他目标。我们的长期目标：地址 未满足的对新型心力衰竭疗法的需求经过商业验证。